Pharma Earnings Preview - Domestic Branded Formulation To Drive Q1: Nirmal Bang
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Nirmal Bang Report
We expect Q1 FY22 revenue and margins to improve for most pharmaceutical companies in our coverage universe, led by strong growth in domestic branded formulation sales.
Domestic formulation year-on-year sales growth was aided by a surge in demand for Covid-19 drugs and a subdued base since Q1 FY21 was a wash-out on account of the nationwide lockdown.
The U.S. revenues remained flattish with most companies growing by less than 2% in volume terms on a sequential QoQ basis.
However, Cipla Ltd. has been an exception as it has registered 5% QoQ volume growth in the U.S. market.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.